The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway
Khan, Abrar Ul Haq
Bozić Stanojević, Milica
Lopez-Mejia, Isabel C.
MetadataShow full item record
Controlling cholesterol levels is a major challenge in human health, since hypercholesterolemia can lead to serious cardiovascular disease. Drugs that target carbohydrate metabolism can also modify lipid metabolism and hence cholesterol plasma levels. In this sense, dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, augments usage of the glycolysis-produced pyruvate in the mitochondria increasing oxidative phosphorylation (OXPHOS). In several animal models, DCA decreases plasma cholesterol and triglycerides. Thus, DCA was used in the 70 s to treat diabetes mellitus, hyperlipoproteinemia and hypercholesterolemia with satisfactory results. However, the mechanism of action remained unknown and we describe it here. DCA increases LDLR mRNA and protein levels as well as LDL intake in several cell lines, primary human hepatocytes and two different mouse models. This effect is mediated by transcriptional activation as evidenced by H3 acetylation on lysine 27 on the LDLR promoter. DCA induces expression of the MAPK ERK5 that turns on the transcription factor MEF2. Inhibition of this ERK5/MEF2 pathway by genetic or pharmacological means decreases LDLR expression and LDL intake. In summary, our results indicate that DCA, by inducing OXPHOS, promotes ERK5/MEF2 activation leading to LDLR expression. The ERK5/MEF2 pathway offers an interesting pharmacological target for drug development.
Is part ofScientific Reports, 2017, vol. 7, p. 10654
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Khan, Abrar Ul Haq et al., 2017
Showing items related by title, author, creator and subject.
Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Bozić Stanojević, Milica; Méndez-Barbero, Nerea; Gutiérrez-Muñoz, Carmen; Betriu i Bars, M. Àngels; Egido, Jesús; Fernández i Giráldez, Elvira; Martín-Ventura, JL.; Valdivielso Revilla, José Manuel; Blanco-Colio, LM. (Elsevier, 2018)BACKGROUND AND AIMS: Vascular calcification (VC) and atherosclerosis are associated with an increased cardiovascular morbimortality in chronic kidney disease (CKD). Osteoprotegerin (OPG) and osteopontin (OPN) are involved ...
Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort Valls, Joan; Cambray Carner, Serafí; Pérez-Guallar, Carles; Bozić Stanojević, Milica; Bermúdez López, Marcelino; Fernández i Giráldez, Elvira; Betriu i Bars, M. Àngels; Rodríguez, Isabel; Valdivielso Revilla, José Manuel (Frontiers Media, 2019)Chronic kidney disease (CKD) is a major risk factor for end-stage renal disease, cardiovascular disease and premature death. Despite classical clinical risk factors for CKD and some genetic risk factors have been identified, ...
Vascular calcification induced by chronic kidney disease is mediated by an increase of 1α-hydroxylase expression in vascular smooth muscle cells Torremadé Pascual, Noèlia; Bozić Stanojević, Milica; Panizo García, Sara; Barrio Vazquez, Sara; Fernandez Martín, José L.; Encinas Martín, Mario; Goltzman, David; Arcidiacono, Maria V.; Fernández i Giráldez, Elvira; Valdivielso Revilla, José Manuel (Wiley, 2016-04-01)Vascular calcification (VC) is a complication of chronic kidney disease that predicts morbidity and mortality. Uremic serum promotes VC, but the mechanism involved is unknown. A role for 1,25(OH)2 D3 in VC has been proposed, ...